IGEA to partner with Acalis for Alz1 wholesale distribution in the US

IGEA and Acalis started to partner on a commercial basis beginning 2020 for exclusive distribution in Middle East and some European and South American countries, including Belgium, Chile, Colombia, Uruguay and Peru, of IGEA's products and solutions. The partnership extends now to the US, where yearly 500'000 people over 65 develop Alzheimer (which is someone every 65 seconds), 5.6 million people over 65 has Alzheimer and 16 million people daily take care about them.

IGEA will continue to distribute Alz1 on its e-commerce platform, and together with this new license agreement, IGEA expects to strengthen the market position of Alz1 with a substantial impact on its net revenues.

Under the terms of the agreement, the commercialization of Alz1 on a wholesale basis is expected to start within the next six months. In addition to supplying Alz1, IGEA will also provide certain services to Acalis including lab testing and data management and get an expected double-digit license fee determined pursuant to a shared risk-reward concept.

Acalis is an international healthcare group whose goal is to maximize the standards of comfort in care around the world. Acalis and AcalisCare are brands that today represent a seal of quality in the field of global elderly care, home care, rehabilitation, and post-hospital support with more than 40 centers, over 3,000 beds and more than 2,600 employees. As such, Acalis is one of the most global private home care and assistance providers in Europe, Latin America and Middle East, in particular Saudi Arabia and Turkey, and is expanding in Asia and North America

About IGEA
IGEA Pharma focuses on health-tech and med-tech products and devices. Health-tech products are exclusively preventative. IGEA commercializes an Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit to measure non-bound copper in the blood and 'Alz1 Tab', a natural dietary supplement designed to reduce blood heavy metals content), and expects to launch a diabetes type II prevention set in 2020. Non-ceruloplasmin bound copper is an expected Alzheimer's and diabetes type II associated biomarker. Determining and regulating non-bound copper can contribute to reduce the risk of Alzheimer's and diabetes type II. Med-tech products focuses on selected solutions and specialities. IGEA operates in air and inanimate environmental surface sanitization with aerosol technology-based devices and expects to start commercializing polymeric based medical bags and other specialty devices for medical use during 2020.
IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands.
igeapharma.nl

Chaineum : Neo Investment Bank
Laurent Leloup : Conférencier blockchain
HealthTech.Finance : HealthTech Investment Bank

This website is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security, nor does it constitute an offer to provide investment advisory or other services by FINYEAR.
No reference to any specific security constitutes a recommendation to buy, sell or hold that security or any other security.
Nothing on this website shall be considered a solicitation or offer to buy or sell any security, future, option or other financial instrument or to offer or provide any investment advice or service to any person in any jurisdiction.
Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell or hold any security. In preparing the information contained in this website, we have not taken into account the investment needs, objectives and financial circumstances of any particular investor.
This information has no regard to the specific investment objectives, financial situation and particular needs of any specific recipient of this information and investments discussed may not be suitable for all investors.
Any views expressed on this website by us were prepared based upon the information available to us at the time such views were written. Changed or additional information could cause such views to change.
All information is subject to possible correction. Information may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances.